Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an Omikron JN.1 angepassten COVID-19-Impfstoff in der Europäischen Union
27 juin 2024 10h30 HE
|
BioNTech SE
Der aktualisierte COVID-19-Impfstoff ist auf die Omikron JN.1-Sublinie von SARS-CoV-2 zugeschnitten und wird für Personen ab 6 Monaten empfohlenDie Beurteilung basiert auf präklinischen und...
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
27 juin 2024 10h30 HE
|
BioNTech SE
The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and olderRecommendation is based on pre-clinical and...
Catch+Release Celebrates Major Wins at the 2024 Telly Awards
03 juin 2024 09h00 HE
|
Catch+Release
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- Catch+Release, the leading content licensing marketplace, proudly announces its remarkable achievements at the 2024 Telly Awards. The company has...
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market
22 mars 2024 10h14 HE
|
Spherix Global Insights
Exton, Pennsylvania, March 22, 2024 (GLOBE NEWSWIRE) -- The end of 2023 introduced several new treatment options for patients suffering from ulcerative colitis (UC). Among them is Eli Lilly’s Omvoh...
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2
18 mars 2024 07h28 HE
|
Arch Biopartners
British Medical Journal Open publishes paper detailing the results of the international Phase II human trial for LSALT peptide targeting acute lung and kidney inflammation in hospitalized patients...
BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action – BNTX
07 mars 2024 15h09 HE
|
The Rosen Law Firm PA
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and...
PARP Inhibitor Market to Surpass USD 67.0 Billion by 2034, with 18.30% CAGR and Redefining Cancer Treatment Landscape - By PMI
27 févr. 2024 14h30 HE
|
PMI
Covina, Feb. 27, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the PARP Inhibitor Market size was valued at about USD 12.5 Billion in 2024 and expected to grow at CAGR of 18.30%...
Charting New Paths: Non-TNF's Evolving in Rheumatoid Arthritis Market
23 févr. 2024 13h50 HE
|
Spherix Global Insights
EXTON, PA, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Amidst the array of advanced treatment avenues available for rheumatoid arthritis (RA), ranging from legacy TNF inhibitors and their newer biosimilar...
Biopharmaceutical and Biomedicine Market Size & Share to Exceed USD 1803.2 Billion by 2034, at CAGR of 12.20%. “Harnessing the Power of Genomics for Precision Medicine"– By PMI
12 févr. 2024 19h30 HE
|
PMI
Covina, Feb. 12, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Biopharmaceutical and Biomedicine Market size was valued at about USD 570.0 Billion in 2024 and expected to...
Remicade Biosimilars Market Size & Share to Exceed USD 34.4 Billion by 2034, at CAGR of 9.30% - By PMI
08 févr. 2024 17h30 HE
|
PMI
Covina, Feb. 08, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Remicade Biosimilars Market size was valued at about USD 15.3 Billion in 2024 and expected to grow at CAGR of...